Ebos Group posts record full-year result
Coronavirus pandemic did not negatively impact Ebos Group's FY20 result.
AdvertisementAdvertise with NZME.
Latest from Ebos Group Limited
Chemist Warehouse helps drive Ebos profit up 22 per cent
No major impact from the coronavirus crisis
'Appalling': Shareholders Association lashes Ebos Group
Shareholders Association lashes out at Ebos.
Ebos profit drops 4 per cent due to one-off costs
The company's underlying profit did, however, increase.
Ebos profit grows to $272 million
Profit for the group grew 10 per cent, despite a dip in revenue.
Ebos posts 4.9pc gain in profit
The pharmaceutical and animal health products maker posted a 4.9 per cent gain in profit.
F&P leads local stocks higher
Other markets don't fare so well after fall in oil price.
Fletcher result drags down sharemarket
A2 Milk stock falls as firm's CEO and chair sell shares.
Ebos boosts first-half profit 7.2pc
Ebos Group's recent acquisitions helped the pharmaceutical and animal health products maker lift first-half profit 7.2 per cent.
Deloitte Top 200: Company of the Year - Ebos
This NZX-listed healthcare distributor has gone through a meteoric phase of growth, completing roughly 20 acquisitions over the past 10 years.
Ebos expands with $80m Red Seal deal
Ebos Group will expand its involvement with natural health products after agreeing to buy New Zealand vitamin and herbal tea maker Red Seal for $80 million.
Oz result boosts Ebos' profit
Ebos Group, the healthcare and animal care products company, posted a 15 per cent gain in full-year profit, led by increased sales and an improved margin from its Australian healthcare businesses.
Ebos shows healthy rise in interim profit
Healthcare and animal care products company Ebos reported a 12 per cent gain in first-half profit after lifting earnings in both its divisions and refinancing debt on more favourable terms.
CEO's reign saw turnover up
Ebos GroupTurnover at medical consumable and pharmaceutical products company Ebos Group has grown from around $8 million to $6 billion in the 27 years since Mark Waller became CEO.
Helen Twose: Ebos chief's long road to growth
When Mark Waller took over the top job at listed healthcare supplier Ebos, he never imagined he'd be dropping the reins 27 years later.
NZX's worst shares of 2014 (+graphic)
What are the top 10 worst performing shares of 2014 so far? Find out with a graphic showing the biggest losers.
Brian Gaynor: Companies must lift earnings performance
The NZX will run out of steam unless companies, particularly the larger ones, can take advantage of the stronger economy, writes Brian Gaynor.
Stock Takes: Research shortfall
Ebos Group's $1.1 billion acquisition of Australian firm Symbion this week again highlighted an ongoing issue with getting independent research on NZX-listed companies.
Brian Gaynor: Changing the scores unfair to investors
Normalising profits to bury the bottom line shouldn't be the norm.